Suzanne Kamel-Reid

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. pmc KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
    D Soulieres
    Centre Hospitalier de l Universite de Montreal, Montreal, Quebec
    Curr Oncol 17:S31-40. 2010
  2. pmc Applications of microarray technology to acute myelogenous leukemia
    Rashmi S Goswami
    Division of Applied Molecular Oncology, Princess Margaret Hospital the Ontario Cancer Institute, University Health Network, Toronto, ON, Canada
    Cancer Inform 7:13-28. 2009
  3. doi Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma
    Suzanne Kamel-Reid
    Molecular Diagnostics Laboratory, Department of Pathology, The University Health Network, Toronto, Ontario, Canada
    Arch Pathol Lab Med 136:26-32. 2012
  4. pmc Postal survey of physicians and laboratories: practices and perceptions of molecular oncology testing
    Fiona A Miller
    Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
    BMC Health Serv Res 9:131. 2009
  5. pmc Programmed cell death 4 loss increases tumor cell invasion and is regulated by miR-21 in oral squamous cell carcinoma
    Patricia P Reis
    Division of Applied Molecular Oncology, Princess Margaret Hospital, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada
    Mol Cancer 9:238. 2010
  6. doi Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia
    Jonathan How
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Cancer 118:6110-7. 2012
  7. ncbi Molecular cytogenetic analysis of head and neck squamous cell carcinoma: By comparative genomic hybridization, spectral karyotyping, and expression array analysis
    Jeremy A Squire
    Department of Laboratory Medicine and Pathobiology, The University of Toronto and The University Health Network, Toronto, Ontario, Canada
    Head Neck 24:874-87. 2002
  8. doi The use of FTA cards for preserving unfixed cytological material for high-throughput molecular analysis
    Mauro Ajaj Saieg
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
    Cancer Cytopathol 120:206-14. 2012
  9. doi A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma
    Benoit You
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, 610 University Avenue, Toronto, Ontario, Canada
    Am J Clin Oncol 35:255-60. 2012
  10. pmc mRNA transcript quantification in archival samples using multiplexed, color-coded probes
    Patricia P Reis
    Division of Applied Molecular Oncology, Princess Margaret Hospital, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada
    BMC Biotechnol 11:46. 2011

Detail Information

Publications77

  1. pmc KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
    D Soulieres
    Centre Hospitalier de l Universite de Montreal, Montreal, Quebec
    Curr Oncol 17:S31-40. 2010
    ..Mutations in the KRAS oncogene have consistently been shown to predict non-response to cetuximab and panitumumab. The role of KRAS as a marker of efficacy of anti-EGFR therapies is reviewed...
  2. pmc Applications of microarray technology to acute myelogenous leukemia
    Rashmi S Goswami
    Division of Applied Molecular Oncology, Princess Margaret Hospital the Ontario Cancer Institute, University Health Network, Toronto, ON, Canada
    Cancer Inform 7:13-28. 2009
    ..Finally, we discuss several new and emerging array technologies, and how they can be further utilized to improve our understanding of AML...
  3. doi Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma
    Suzanne Kamel-Reid
    Molecular Diagnostics Laboratory, Department of Pathology, The University Health Network, Toronto, Ontario, Canada
    Arch Pathol Lab Med 136:26-32. 2012
    ..For assays that are not approved by the US Food and Drug Administration, the performance characteristics of the assay must be determined and validated by the clinical laboratory before implementation...
  4. pmc Postal survey of physicians and laboratories: practices and perceptions of molecular oncology testing
    Fiona A Miller
    Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
    BMC Health Serv Res 9:131. 2009
    ..Yet knowledge limitations regarding the delivery of testing services may constrain the translation of scientific advancements into effective health care...
  5. pmc Programmed cell death 4 loss increases tumor cell invasion and is regulated by miR-21 in oral squamous cell carcinoma
    Patricia P Reis
    Division of Applied Molecular Oncology, Princess Margaret Hospital, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada
    Mol Cancer 9:238. 2010
    ..We also examined PDCD4 regulation by microRNA 21 (miR-21) in OSCC...
  6. doi Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia
    Jonathan How
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Cancer 118:6110-7. 2012
    ....
  7. ncbi Molecular cytogenetic analysis of head and neck squamous cell carcinoma: By comparative genomic hybridization, spectral karyotyping, and expression array analysis
    Jeremy A Squire
    Department of Laboratory Medicine and Pathobiology, The University of Toronto and The University Health Network, Toronto, Ontario, Canada
    Head Neck 24:874-87. 2002
    ..Such combinatorial studies may help to identify recurrent patterns of altered gene expression in the context of specific chromosomal changes...
  8. doi The use of FTA cards for preserving unfixed cytological material for high-throughput molecular analysis
    Mauro Ajaj Saieg
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
    Cancer Cytopathol 120:206-14. 2012
    ....
  9. doi A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma
    Benoit You
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, 610 University Avenue, Toronto, Ontario, Canada
    Am J Clin Oncol 35:255-60. 2012
    ..A phase II trial was conducted to determine the efficacy of erlotinib, given as maintenance therapy after gemcitabine-platinum chemotherapy in patients with RM NPC...
  10. pmc mRNA transcript quantification in archival samples using multiplexed, color-coded probes
    Patricia P Reis
    Division of Applied Molecular Oncology, Princess Margaret Hospital, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada
    BMC Biotechnol 11:46. 2011
    ..We assessed the ability of this technology for mRNA expression quantification in archived formalin-fixed, paraffin-embedded (FFPE) oral carcinoma samples...
  11. doi Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype
    Jennifer Luo
    Departments of 1Laboratory Hematology, University Health Network, and Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada
    Am J Clin Pathol 133:34-40. 2010
    ..Our data confirm that cytoplasmic NPM1 immunoreactivity predicts NPM1 mutations and warrants inclusion in the routine diagnostic and prognostic workup of AML...
  12. pmc A gene signature in histologically normal surgical margins is predictive of oral carcinoma recurrence
    Patricia P Reis
    Div, of Applied Molecular Oncology, Princess Margaret Hospital, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada
    BMC Cancer 11:437. 2011
    ..Therefore, molecular analysis of histologically normal resection margins and the corresponding OSCC may aid in identifying a gene signature predictive of recurrence...
  13. ncbi Epstein-Barr virus DNA measured in nasopharyngeal brushings in patients with nasopharyngeal carcinoma: pilot study
    Antti A Makitie
    Department of Cellular and Molecular Biology, Wharton Head and Neck Center, Ontario Cancer Institute and Princess Margaret Hospital, Toronto, ON
    J Otolaryngol 33:299-303. 2004
    ..We measured the amount of tumour-derived Epstein-Barr virus (EBV) deoxyribonucleic acid (DNA) in the nasal brushings of nasopharyngeal carcinoma (NPC) patients to determine the correlation with tumour load and response to treatment...
  14. doi Correlation among nuclear localization of NuMA-RARα, deregulation of gene expression and leukemic phenotype of hCG-NuMA-RARα transgenic mice
    Mahadeo A Sukhai
    Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
    Leuk Res 35:670-6. 2011
    ..1. Finally, we report that phenotype onset is correlated with NuMA-RARα copy number; mice with higher copy number developing disease later than those with lower copy number...
  15. ncbi Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
    Chang Qi Zhu
    FRCPC, Princess Margaret Hospital, 610 University Ave, Toronto, Ontario, Canada M5G 2M9
    J Clin Oncol 26:4268-75. 2008
    ..To evaluate the effect of KRAS and epidermal growth factor receptor (EGFR) genotype on the response to erlotinib treatment in the BR.21, placebo-controlled trial...
  16. doi Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3
    Gilda da Cunha Santos
    Department of Pathology, University Health Network, Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Ontario, Canada
    Cancer 116:5599-607. 2010
    ..Mutation status of the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) and EGFR gene copy number (GCN) were evaluated as predictive markers in 26% of patients who had tumor samples available for analysis...
  17. doi Claudin 1 overexpression increases invasion and is associated with aggressive histological features in oral squamous cell carcinoma
    Patricia Pintor dos Reis
    Division of Applied Molecular Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    Cancer 113:3169-80. 2008
    ..Their goal was to examine CLDN1 expression in a large series of primary OSCCs and to further investigate whether CLDN1 overexpression plays a role in invasion in OSCC...
  18. pmc The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Nicole G Chau
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    Head Neck Oncol 3:11. 2011
    ....
  19. doi Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: which parameter at which time-point does matter?
    Dong Hwan Dennis Kim
    Chronic Myelogenous Leukemia Group, Department of Hematology Medical Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Am J Hematol 85:856-62. 2010
    ..The patient who achieves short-term response rapidly will have a lower risk of losing response or failing after imatinib therapy in CML patients...
  20. ncbi Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years)
    Bruno C Medeiros
    Department of Medical Oncology, Peincess Margaret Hospital, University Health Network, Univeristy of Toronto, Toronto, Ontario, Canada
    Leuk Lymphoma 48:65-71. 2007
    ..We conclude that very late-relapse AML is a rare event, and that reinduction in these patients is associated with very high CR rates and a potential cure fraction...
  21. pmc Low prevalence of human papillomavirus in oral cavity carcinomas
    Jerry Machado
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
    Head Neck Oncol 2:6. 2010
    ..Increasing evidence shows that Human Papillomavirus (HPV) is preferentially associated with some head and neck squamous cell carcinomas (HNSCCs), with variable infection rates reported...
  22. pmc Optimization and analysis of a quantitative real-time PCR-based technique to determine microRNA expression in formalin-fixed paraffin-embedded samples
    Rashmi S Goswami
    Division of Applied Molecular Oncology, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada
    BMC Biotechnol 10:47. 2010
    ..miRs may be less prone to degradation during formalin fixation, facilitating miR expression studies in formalin-fixed paraffin-embedded (FFPE) tissue...
  23. pmc A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors
    Ivan Diaz-Padilla
    Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, 610 University Avenue, 5 125, M5G 2M9, Toronto, ON, Canada
    Invest New Drugs 31:1182-91. 2013
    ..To determine the recommended phase II dose (RP2D) and assess the safety, pharmacokinetics (PKs) and pharmacodynamics of RO4929097in combination with temsirolimus...
  24. pmc microRNA evaluation of unknown primary lesions in the head and neck
    Emma V Barker
    Department of Applied Molecular Oncology, Princess Margaret Hospital, Ontario Cancer Institute and University Health Network, Toronto, Ontario M5G 2M9, Canada
    Mol Cancer 8:127. 2009
    ..This may be clinically relevant to predict the primary site of origin of metastatic disease, when the primary site remains obscure...
  25. pmc Recurrent genomic alterations in sequential progressive leukoplakia and oral cancer: drivers of oral tumorigenesis?
    Nilva K Cervigne
    Division of Applied Molecular Oncology, Ontario Cancer Institute
    Hum Mol Genet 23:2618-28. 2014
    ..BTBD7, KHDRBS1, PARP1 and RAB1A may be associated with OSCC progression. Protein-protein interaction networks were created to identify possible pathways associated with OSCC progression. ..
  26. ncbi Molecular classification of oral cancer by cDNA microarrays identifies overexpressed genes correlated with nodal metastasis
    Giles C Warner
    Department of Cellular and Molecular Biology, Princess Margaret Hospital, Ontario Cancer Institute, University Health Network, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada
    Int J Cancer 110:857-68. 2004
    ..Application of this methodology represents an advance in the classification of oral cavity tumors and may ultimately aid in the development of more tailored therapies for oral carcinoma...
  27. doi CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia
    Harry Dang
    Department of Laboratory Hematology, University Health Network, Toronto, Ontario, Canada M5G 2C4 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada M5S 1A1
    Hum Pathol 44:2038-46. 2013
    ..027) in the FLT3-ITD-positive group. Our results confirm the prognostic value of assessing FLT3-ITD mutations in NPM1-positive AML and identify the adverse prognostic impact of high WBC and CD34 expression in this subgroup of AML. ..
  28. doi Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation
    Allan Jiang
    Department of Laboratory Hematology, University Health Network, Toronto, ON, Canada
    Leuk Res 35:492-8. 2011
    ..045 and P=0.028, respectively), and CD56 positivity predicted shorter EFS (P=0.012). Our results confirm the favorable impact of NPM1 mutations and identify the adverse prognostic relevance of CD56 expression in this subgroup of AML...
  29. ncbi Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib
    Mark Agulnik
    Princess Margaret Hospital Phase II Consortium, Toronto, Ontario, Canada
    J Clin Oncol 25:2184-90. 2007
    ..Additional biomarker studies with larger sample sizes are required to elucidate HNSCC patients who may benefit from this targeted therapy...
  30. ncbi BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib
    Dennis D Kim
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON, Canada
    Br J Haematol 160:630-9. 2013
    ..In conclusion, the BCR-ABL1 transcript level at 3 months is the most relevant surrogate for outcomes following 2GTKI therapy after Imatinib failure...
  31. doi Clinical genomics information management software linking cancer genome sequence and clinical decisions
    Stuart Watt
    Ontario Institute for Cancer Research, Toronto, Ontario, Canada
    Genomics 102:140-7. 2013
    ....
  32. doi MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma
    Rashmi S Goswami
    Ontario Cancer Institute, University Health Network
    J Clin Oncol 31:2903-11. 2013
    ..MicroRNAs (miRs) are useful in prognostic assessment of cancer. We determined an miR signature defining aggressiveness in B-cell non-Hodgkin lymphomas (NHL) and assessed whether this signature aids in MCL prognosis...
  33. doi Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial
    Ben Tran
    Department of Medical Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Int J Cancer 132:1547-55. 2013
    ..Additionally, actionable mutations identified in this study were relatively stable between archival and biopsy samples, implying that cancer mutations that are good predictors of drug response may remain constant across clinical stages...
  34. ncbi Molecular characterization of salivary gland malignancy using the Smgb-Tag transgenic mouse model
    Antti A Makitie
    Department of Cellular and Molecular Biology, Ontario Cancer Institute and Princess Margaret Hospital, The University Health Network, Toronto, Ontario, Canada
    Lab Invest 85:947-61. 2005
    ..Our data suggest that Ptn and Cd24a may be genetic markers associated with salivary gland tumorigenesis and/or progression...
  35. doi Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma
    Nilva K Cervigne
    Division of Applied Molecular Oncology, Toronto General Hospital, Ontario Cancer Institute, The University Health Network, Toronto, ON, Canada
    Hum Mol Genet 18:4818-29. 2009
    ..Our study provides the first evidence of an miR signature potentially useful for identifying leukoplakias at risk of malignant transformation...
  36. pmc Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group
    Amit M Oza
    Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 29:3278-85. 2011
    ..Temsirolimus, an ester derivative of rapamycin that inhibits mTOR, was evaluated in this setting...
  37. doi Detection of EGFR and KRAS mutations in fine-needle aspirates stored on Whatman FTA cards: is this the tool for biobanking cytological samples in the molecular era?
    Gilda da Cunha Santos
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
    Cancer Cytopathol 118:450-6. 2010
    ....
  38. ncbi Lymphatic vessel density, nodal metastases, and prognosis in patients with head and neck cancer
    Nathalie Audet
    Department of Otolaryngology, Wharton Head and Neck Centre, Princess Margaret Hospital, University of Toronto, Ontario, Canada
    Arch Otolaryngol Head Neck Surg 131:1065-70. 2005
    ..To examine the relationship between intratumoral lymphatic vessel density and clinical and pathological variables in patients with head and neck squamous cell carcinoma...
  39. doi Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation
    Arwa Abdelhameed
    Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada
    Cancer 112:1513-21. 2008
    ..Evaluation of therapeutic outcomes and risk factors was undertaken for patients with primary solid tumors (PST) developing acute leukemia or myelodysplasia (MDS) as a second malignancy...
  40. ncbi Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stem cell transplantation
    Bruno C Medeiros
    Department of Medical Oncology and Hematology, Princess Margaret Hospital University Health Network, Toronto, Ontario, Canada
    Am J Hematol 82:758-60. 2007
    ..Evaluation of the donor demonstrated no dysplasia or cytogenetic abnormalities. This observation reinforces the possibility that IM therapy may be casually linked to the phenomenon of secondary cytogenetic changes in diploid cells...
  41. doi Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype
    Harry Dang
    Department of Laboratory Hematology, University Health Network, Toronto, Ontario, Canada
    Hum Pathol 44:55-61. 2013
    ..By combining genetic and immunophenotypic markers, we can divide patients into distinct prognostic groups with important implications for prognostic stratification and risk-adapted therapy...
  42. ncbi Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older
    Vikas Gupta
    Blood and Marrow Transplant Program, Princess Margaret Hospital, Toronto, Ontario, Canada
    Biol Blood Marrow Transplant 11:764-72. 2005
    ..The reasonable disease control with nonmyeloablative transplantation in this high-risk group of patients merits further investigation...
  43. ncbi Correlation of Epstein-Barr virus DNA in cell-free plasma, functional imaging and clinical course in locally advanced nasopharyngeal cancer: a pilot study
    Antti A Makitie
    Princess Margaret Hospital, Ontario Cancer Institute, University Health Network, 610 University Ave, Suite 5 210, Toronto, M5G 2M9, Canada
    Head Neck 26:815-22. 2004
    ....
  44. doi Cancer genomics: technology, discovery, and translation
    Ben Tran
    FRCPC, Princess Margaret Hospital, Drug Development Program, 610 University Ave, Ste 5 718, Toronto, Ontario, M5G 2M9, Canada
    J Clin Oncol 30:647-60. 2012
    ....
  45. ncbi Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RARalpha
    Mahadeo A Sukhai
    Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
    Oncogene 23:665-78. 2004
    ..The phenotype of transgenic mice was consistent with a blockade of neutrophil differentiation. NuMA-RARalpha is therefore sufficient for disease development in this APL model...
  46. ncbi Precursor lymphoblastic lymphoma reoccurring as a donor-derived neoplasm: a case report and review of the literature
    Brendan C Dickson
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    Arch Pathol Lab Med 132:1342-5. 2008
    ..We offer the report of a patient with an unusual lymphoblastic lymphoma who, after successful bone marrow transplantation, developed the same disease of donor cell origin; further, we offer a literature review on donor cell lymphoma...
  47. doi Targeted use of fluorescence in situ hybridization (FISH) in cytospin preparations: results of 298 fine needle aspirates of B-cell non-Hodgkin lymphoma
    Gilda da Cunha Santos
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada
    Cancer Cytopathol 118:250-8. 2010
    ....
  48. ncbi A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix
    Jennifer J Knox
    Departments of Medical Oncology, Princess Margaret Hospital, Ontario Cancer Institute, University Health Network, 5 218, 610 University Avenue, Toronto, Ont, Canada M5G 2M9
    Eur J Cancer 41:523-30. 2005
    ..We conclude that the administration of lovastatin at 7.5 mg/kg/day for 21 consecutive days on a 28-day schedule is well tolerated in patients with good renal function and warrants further clinical evaluation...
  49. doi The aryl hydrocarbon receptor nuclear translocator (ARNT) modulates the antioxidant response in AML cells
    Chunhong Gu
    The J Douglas Crashley MDS Research Laboratory, Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada
    Leuk Res 37:1750-6. 2013
    ..Our results indicate that ARNT expression in AML cells augments antioxidant response and confers resistance to ROS inducers. This suggests ARNT may modulate ROS signaling and drug response in AML. ..
  50. pmc Equivocal p16 immunostaining in squamous cell carcinoma of the head and neck: staining patterns are suggestive of HPV status
    Zhongchuan Will Chen
    Department of Laboratory Medicine and Pathobiology, University Health Network, University of Toronto, Toronto, ON, Canada
    Head Neck Pathol 6:422-9. 2012
    ..The HPV-positive cases determined by staining pattern were also associated with a higher percentage of stained tumor cells...
  51. ncbi Expression of NPM-RARalpha fusion gene in hematopoietic cells confers sensitivity to troglitazone-induced apoptosis
    Suzanne Kamel-Reid
    The Department of Cellular and Molecular Biology, The Ontario Cancer Institute, The University Health Network, Toronto, Ontario, Canada M5G 2M9
    Oncogene 22:6424-35. 2003
    ..We conclude that in the presence of X-RARalpha, TG induces cell death due to apoptosis via the caspase pathway. These observations suggest the investigation of PPARgamma ligands as therapeutic agents in acute leukemia...
  52. ncbi No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia
    Dong Hwan Dennis Kim
    Chronic Myelogenous Leukemia Group, Department of Hematology Medical Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Cancer 113:772-81. 2008
    ....
  53. ncbi Sample features associated with success rates in population-based EGFR mutation testing
    Carolyn J Shiau
    Department of Pathology, University Health Network, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada Department of Pathology, Royal Columbian Hospital, New Westminster, British Columbia, Canada Department of Biostatistics, University Health Network, and Princess Margaret Cancer Centre, Toronto, Ontario, Canada and Division of Hematology and Medical Oncology, Princess Margaret Cancer Centre, and Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    J Thorac Oncol 9:947-56. 2014
    ....
  54. doi A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation
    Mohamed Shanavas
    Allogeneic Blood and Marrow Transplantation Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada Electronic address
    Clin Lymphoma Myeloma Leuk 14:87-92. 2014
    ....
  55. pmc Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations
    Tong Zhang
    Department of Pathology, The University Health Network, Toronto, Ontario, Canada
    J Mol Diagn 9:421-30. 2007
    ..Our study emphasizes the need for optimization of real-time qRT-PCR before offering clinical testing and the need for widely available universal standards that can be used for test calibration...
  56. ncbi Cryptic insertion of MLL gene into 9p22 leads to MLL-MLLT3 (AF9) fusion in a case of acute myelogenous leukemia
    Mary Shago
    Department of Paediatric Laboratory Medicine, Hospital for Sick Children, Toronto, Ontario, Canada
    Genes Chromosomes Cancer 40:349-54. 2004
    ..RT-PCR was used to show that the cryptic rearrangement in this patient led to the fusion of the MLL and MLLT3 transcripts on the der(9). The presence of the MLL-MLLT3 transcript is consistent with the clinical findings in this patient...
  57. ncbi Absence of FTL3 mutations in patients with JAK2V617F mutation negative essential thrombocythemia
    Bruno C Medeiros
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    Am J Hematol 82:293-4. 2007
    ....
  58. doi A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study
    Michael Crump
    National Cancer Institute of Canada Clinical Trials Group
    Leuk Lymphoma 51:252-60. 2010
    ..Flow cytometry studies suggest that sorafenib inhibits ERK phosphorylation via c-KIT. The recommended phase II dose in AML is 300 mg BID continuously, and testing in combination and in FLT3-ITD AML is warranted...
  59. ncbi Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer
    Helen J Mackay
    Princess Margaret Hospital, Toronto, Ontario, Canada
    Cancer 120:603-10. 2014
    ..The aim of this study was to identify molecular markers associated with mTOR inhibitor activity in women with metastatic endometrial cancer...
  60. ncbi Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen
    John M Storring
    Department of Medical Oncology and Haematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
    Br J Haematol 146:76-85. 2009
    ..Effective delivery of asparaginase dosing appears to be important in achieving an optimal antileukaemic effect...
  61. ncbi Current applications of microarrays in head and neck cancer research
    Giles C Warner
    Department of Cellular and Molecular Biology, Ontario Cancer Institute and Princess Margaret Hospital, University Health Network and University of Toronto, Toronto, Ontario, Canada
    Laryngoscope 114:241-8. 2004
    ..The objective was to introduce microarray technology and its applications in cancer research to the head and neck clinician...
  62. ncbi Vanishing endometrial carcinoma
    Valerie Dube
    Department of Pathology, Mount Sinai Hospital, Toronto, Ontario, Canada
    Int J Gynecol Pathol 26:271-7. 2007
    ..Vanishing EmCa is only a small subset within hysterectomy specimens that show no EmCa after a histological diagnosis of EmCa. The concept of vanishing EmCa may be useful in both clinical and medicolegal practice...
  63. ncbi Acute leukemia of donor origin arising after stem cell transplantation for acute promyelocytic leukemia
    Andrew S Daly
    Allogeneic Bone Marrow Transplant Service, Department of Medical Oncology and Hematology, Princess Margaret Hospital University Health Network, Toronto, Ont, Canada
    Leuk Res 28:1107-11. 2004
    ..To our knowledge, this is the first report of donor cell leukemia following BMT for APL. We hypothesize that replicative stress may lead to the development of some cases of donor cell acute leukemia...
  64. ncbi Erlotinib in lung cancer - molecular and clinical predictors of outcome
    Ming Sound Tsao
    University Health Network, Princess Margaret Hospital Site, and the Ontario Cancer Institute, University of Toronto, Canada
    N Engl J Med 353:133-44. 2005
    ....
  65. ncbi A novel method of measuring gas phase nitric oxide concentration in cell cultures
    Antti A Makitie
    Department of Otolaryngology Head and Neck Surgery, University of Toronto, Toronto, Ont, Canada
    Acta Otolaryngol 125:1086-90. 2005
    ..Elevated levels of the gas phase NO concentration were consistently obtained from the cell culture flasks using this experimental set-up. Hypoxia and radiation diminished NO production...
  66. doi Interleukin-21 has activity in patients with metastatic melanoma: a phase II study
    Teresa M Petrella
    Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada M4N 3M5
    J Clin Oncol 30:3396-401. 2012
    ..We report a multicenter phase II study of patients with metastatic melanoma (MM), evaluating the efficacy, toxicity, progression-free survival (PFS), immunogenicity, and biomarker profile of interleukin-21 (IL-21)...
  67. doi Therapy-related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis
    Amal Abdulwahab
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada
    Cancer 118:3962-7. 2012
    ..Acute lymphoblastic leukemia (ALL) occurring in patients with a history of prior chemotherapy/radiotherapy exposure has been previously reported to be rare, accounting for <2.5% of ALL cases...
  68. doi An emerging role for retinoid X receptor α in malignant hematopoiesis
    Mariam Thomas
    Princess Margaret Hospital the Ontario Cancer Institute, University Health Network, Toronto, ON, Canada
    Leuk Res 36:1075-81. 2012
    ..In this review we highlight recent studies that clarify the role of RXR alpha in normal and malignant hematopoiesis...
  69. pmc SATB2 augments ΔNp63α in head and neck squamous cell carcinoma
    Jacky Chung
    Department of Molecular Genetics, University of Toronto, Cell Biology Program, Hospital for Sick Children Research Institute, Department of Paediatrics, 555 University Avenue, Toronto, Ontario, M5G 1L7, Canada
    EMBO Rep 11:777-83. 2010
    ..These findings unveil SATB2 as a pivotal modulator of ΔNp63α that governs HNSCC cell survival...
  70. pmc Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia
    Dong Hwan Kim
    Chronic Myelogenous Leukemia Group, Department of Hematology Medical Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Haematologica 94:135-9. 2009
    ....
  71. ncbi Molecular analysis of a new variant of the CBF beta-MYH11 gene fusion
    Jennifer Stulberg
    Department of Cellular and Molecular Biology, Ontario Cancer Institute, Toronto, Ont, Canada
    Leuk Lymphoma 43:2021-6. 2002
    ..Molecular diagnostic facilities should be aware of the existence of the CBFbeta(486)/MYH11(1591) variant and its potential association with the previously described type E fusion...
  72. ncbi Early hematopoietic reconstitution after clinical stem cell transplantation: evidence for stochastic stem cell behavior and limited acceleration in telomere loss
    Ian Thornley
    Division of Hematology Oncology, The Hospital for Sick Children, University Health Network, University of Toronto, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada
    Blood 99:2387-96. 2002
    ....
  73. ncbi A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies
    Aaron D Schimmer
    Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Ontario, Canada
    Clin Cancer Res 14:8295-301. 2008
    ..Therefore, we conducted a phase I clinical trial of the small-molecule pan-Bcl-2 inhibitor, obatoclax mesylate, in patients with refractory leukemia and myelodysplasia to assess its safety and define its optimal dose...
  74. ncbi Lung transplantation complicated by graft-versus-host disease and confounded by incidental transfusion-associated macrochimerism
    Katerina Pavenski
    Department of Medicine, McMaster University, Canadian Blood Services, Hamilton, Ontario, Canada
    Transfusion 48:2190-6. 2008
    ..This case report illustrates the challenge of a patient who presented with macrochimerism both from the lung transplant allograft and from transfusions...
  75. ncbi T-cell large granular lymphocytic leukemia of donor origin occurring after allogeneic bone marrow transplantation for B-cell lymphoproliferative disorders
    Hong Chang
    Department of Laboratory Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, ON, Canada
    Am J Clin Pathol 123:196-9. 2005
    ..These data show that T-LGL leukemia should be included as one of the types of posttransplantation lymphoproliferative disorders that can occur after allogeneic BMT for B-cell neoplasms...
  76. pmc Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas
    Jim Dimitroulakos
    Department of Cellular and Molecular Biology, The University Health Network, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    Neoplasia 4:337-46. 2002
    ..Our data suggest that the depletion of nonsterol mevalonate metabolites, particularly GGPP, can be potential mediators of lovastatin-induced apoptosis of HNSCC and CC cells...
  77. ncbi The Retinoic acid receptor alpha (RARalpha) chimeric proteins PML-, PLZF-, NPM-, and NuMA-RARalpha have distinct intracellular localization patterns
    Jeff L Hummel
    The Institute of Medical Sciences, University of Toronto, Ontario, M5S 1A8, Canada
    Cell Growth Differ 13:173-83. 2002
    ....